CA2602730A1 - Defective sindbis viral vectors - Google Patents
Defective sindbis viral vectors Download PDFInfo
- Publication number
- CA2602730A1 CA2602730A1 CA002602730A CA2602730A CA2602730A1 CA 2602730 A1 CA2602730 A1 CA 2602730A1 CA 002602730 A CA002602730 A CA 002602730A CA 2602730 A CA2602730 A CA 2602730A CA 2602730 A1 CA2602730 A1 CA 2602730A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- nucleotide sequence
- set forth
- mut
- defective sindbis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36161—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Disclosed herein are new defective Sindbis viral vectors made from wild type Ar-339 Sindbis virus, with differences in replicase and envelope proteins between JT vectors and consensus Sindbis virus sequences, and also between JT
and Ar-339 vectors. Also disclosed are plasmids used for the production of the vectors, methods for producing the vectors, methods for treating mammals suffering from tumors and pharmaceutical formulations for use in the treatment methods.
and Ar-339 vectors. Also disclosed are plasmids used for the production of the vectors, methods for producing the vectors, methods for treating mammals suffering from tumors and pharmaceutical formulations for use in the treatment methods.
Claims (15)
1. A purified, isolated nucleic acid coinprising a nucleotide sequence as set forth in SEQ ID
NO.37 (SP6-H).
NO.37 (SP6-H).
2. A purified, isolated nucleic acid comprising a nucleotide sequence as set forth in SEQ ID
NO.38 (SP6-H-K70).
NO.38 (SP6-H-K70).
3. A purified, isolated nucleic acid comprising a nucleotide sequence as set forth in SEQ ID
NO.40 (SP6-H-K70-V251).
NO.40 (SP6-H-K70-V251).
4. A purified, isolated nucleic acid comprising a nucleotide sequence as set forth in SEQ ID
NO:39 (SP6-H-13-K70-E181-Val 251).
NO:39 (SP6-H-13-K70-E181-Val 251).
5. A purified isolated nucleic acid comprising a nucleotide sequence as set forth in SEQ ID NO:
36 (SP6-R).
36 (SP6-R).
6. A method for producing defective Sindbis viral vectors comprising the steps of (a) providing a linearized replicon plasmid comprising the nucleotide sequence as set forth in SEQ ID NO: 36 and a linearized Helper plasmid selected from SEQ ID
NO:
37, SEQ ID NO: 38, SEQ ID NO: 40 and SEQ ID NO: 39;
(b) transcribing said replicon plasmid and one Helper plasmid to produce RNA;
(c) collecting the RNA transcribed in step (b) and transfecting cells with said RNA;
(d) incubating said transfected cells for a time and at a temperature effective for producing defective Sindbis viral vectors; and (e) collecting said defective Sindbis viral vectors from the medium of said transfected cells.
NO:
37, SEQ ID NO: 38, SEQ ID NO: 40 and SEQ ID NO: 39;
(b) transcribing said replicon plasmid and one Helper plasmid to produce RNA;
(c) collecting the RNA transcribed in step (b) and transfecting cells with said RNA;
(d) incubating said transfected cells for a time and at a temperature effective for producing defective Sindbis viral vectors; and (e) collecting said defective Sindbis viral vectors from the medium of said transfected cells.
7. The method of claim 6 wherein said Helper plasmid comprises the nucleotide sequence as set forth in SEQ ID NO: 38.
8. The method of claim 6 wherein said Helper plasmid comprises the nucleotide sequence as set forth in SEQ ID NO: 40.
9. The method of claim 6 wherein said Helper plasmid comprises the nucleotide sequence as set forth in SEQ ID NO: 39.
10. The method of claim 6 wherein said Helper plasmid comprises the nucleotide sequence as set forth in SEQ ID NO: 37.
11. A defective Sindbis viral vector produced by the method of claim 6.
12. The defective Sindbis vector of claim 11 wherein said vector is selected from Mut-1, Mut-2 and Mut-4.
13. The method of claim 6 wherein said cell is selected from BHK-21, ES-2, ES-2/Fluc and MOSEC cells.
14. A method for treating a mammal suffering from a tumor comprising administering to a mammal in need of such treatment a therapeutically effective amount of a defective Sindbis viral vector selected from Vector C, Mut-1, Mut-2 and Mut-4.
15. A pharmaceutical formulation for treating a mammal suffering from a tumor comprising a defective Sindbis viral vector selected from Vector C, Mut-1, Mut-2 and Mut-4 and a pharmaceutically acceptable carrier or diluent.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66643205P | 2005-03-29 | 2005-03-29 | |
| US60/666,432 | 2005-03-29 | ||
| US75542805P | 2005-12-30 | 2005-12-30 | |
| US60/755,428 | 2005-12-30 | ||
| PCT/US2006/011617 WO2006105279A2 (en) | 2005-03-29 | 2006-03-29 | Defective sindbis viral vectors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2602730A1 true CA2602730A1 (en) | 2006-10-05 |
| CA2602730C CA2602730C (en) | 2012-03-27 |
Family
ID=37054122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2602730A Expired - Fee Related CA2602730C (en) | 2005-03-29 | 2006-03-29 | Defective sindbis viral vectors |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US7303898B2 (en) |
| EP (1) | EP1871425B1 (en) |
| JP (1) | JP4729615B2 (en) |
| AU (1) | AU2006230354B2 (en) |
| CA (1) | CA2602730C (en) |
| IL (1) | IL186234A (en) |
| MX (1) | MX2007012176A (en) |
| WO (1) | WO2006105279A2 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8282916B2 (en) * | 2008-02-21 | 2012-10-09 | New York University | Tumor therapy with replication competent sindbis viral vectors |
| WO2010005704A2 (en) * | 2008-06-13 | 2010-01-14 | New York University | Novel helper plasmid, defective sindbis viral vectors and methods of use thereof |
| EP3589312A1 (en) | 2017-03-03 | 2020-01-08 | New York University | Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins |
| EP3762023A4 (en) | 2018-03-05 | 2021-12-29 | New York University | Induction and enhancement of antitumor immunity involving sindbis virus vectors expressing immune checkpoint proteins |
| WO2021007276A1 (en) | 2019-07-08 | 2021-01-14 | New York University | Tumor immunotherapy using sindbis viral vectors and agonist monoclonal antibodies |
| CN116286983A (en) * | 2023-01-18 | 2023-06-23 | 中国科学院深圳先进技术研究院 | SINV vector expressing IL-7 and its application in the preparation of antitumor drugs |
| WO2025171152A1 (en) * | 2024-02-06 | 2025-08-14 | Amplitude Therapeutics, Inc. | Trans-replicating and self-replicating rnas comprising a modified 5' utr region |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5091309A (en) | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
| US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
| SE9003978D0 (en) | 1990-12-13 | 1990-12-13 | Henrik Garoff | DNA EXPRESSION SYSTEM BASED ON A VIRUS REPLICATION |
| US6770283B1 (en) | 1990-12-13 | 2004-08-03 | Bioption Ab | DNA expression systems based on alphaviruses |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| SE9401091D0 (en) | 1994-03-31 | 1994-03-31 | Bioption Ab | Alphavirus cDNA vectors |
| SE9401709D0 (en) | 1994-05-18 | 1994-05-18 | Mathilda Sjoeberg | Improved alphavirus vectors for expression of heterologous DNA |
| US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| US6458560B1 (en) | 1996-04-05 | 2002-10-01 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| AU9603898A (en) | 1997-10-09 | 1999-05-03 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| US6197502B1 (en) * | 1997-11-17 | 2001-03-06 | Cytos Biotechnology Ag | Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property |
| WO1999044423A1 (en) | 1998-03-03 | 1999-09-10 | The Uab Research Foundation | Amplification of gene transfer and gene therapy by controlled replication |
| FI109847B (en) * | 1998-06-11 | 2002-10-15 | Abb Oy | Procedure for minimizing the error in a synchronous motor rotor angle estimate |
| WO2000039318A1 (en) | 1998-12-31 | 2000-07-06 | Chiron Corporation | Compositions and methods for packaging of alphavirus vectors |
| US6329201B1 (en) | 1998-12-31 | 2001-12-11 | Chiron Corporation | Compositions and methods for packaging of alphavirus vectors |
| CA2370187C (en) | 1999-04-15 | 2011-08-02 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| US6730297B1 (en) | 1999-05-28 | 2004-05-04 | Chiron Corporation | Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders |
| AU7938900A (en) | 1999-10-27 | 2001-05-08 | Cytos Biotechnology Ag | Method for creating divergent populations of nucleic acid molecules and proteins |
| WO2002044394A2 (en) * | 2000-11-29 | 2002-06-06 | University Of Southern California | Targetet retoviral vectors for cancer immunotherapy |
| AU2002306736A1 (en) | 2001-03-16 | 2002-10-03 | Johns Hopkins University | A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same |
| WO2002076468A1 (en) | 2001-03-27 | 2002-10-03 | New York University | Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors |
-
2006
- 2006-03-28 US US11/392,926 patent/US7303898B2/en active Active
- 2006-03-29 WO PCT/US2006/011617 patent/WO2006105279A2/en not_active Ceased
- 2006-03-29 EP EP06748926.0A patent/EP1871425B1/en not_active Not-in-force
- 2006-03-29 JP JP2008504347A patent/JP4729615B2/en not_active Expired - Fee Related
- 2006-03-29 CA CA2602730A patent/CA2602730C/en not_active Expired - Fee Related
- 2006-03-29 MX MX2007012176A patent/MX2007012176A/en active IP Right Grant
- 2006-03-29 AU AU2006230354A patent/AU2006230354B2/en not_active Ceased
-
2007
- 2007-09-24 IL IL186234A patent/IL186234A/en not_active IP Right Cessation
- 2007-10-22 US US11/876,522 patent/US20080161261A1/en not_active Abandoned
- 2007-10-23 US US11/877,018 patent/US8530232B2/en not_active Expired - Fee Related
-
2008
- 2008-05-20 US US12/123,790 patent/US20080300394A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007012176A (en) | 2007-12-13 |
| WO2006105279A9 (en) | 2007-01-25 |
| US20080161261A1 (en) | 2008-07-03 |
| EP1871425A2 (en) | 2008-01-02 |
| CA2602730C (en) | 2012-03-27 |
| US20070020236A1 (en) | 2007-01-25 |
| US7303898B2 (en) | 2007-12-04 |
| EP1871425A4 (en) | 2009-09-30 |
| WO2006105279A3 (en) | 2009-04-16 |
| US20080300394A1 (en) | 2008-12-04 |
| EP1871425B1 (en) | 2014-04-30 |
| HK1115811A1 (en) | 2008-12-12 |
| WO2006105279A2 (en) | 2006-10-05 |
| IL186234A (en) | 2012-08-30 |
| US8530232B2 (en) | 2013-09-10 |
| AU2006230354B2 (en) | 2010-10-28 |
| US20080096837A1 (en) | 2008-04-24 |
| AU2006230354A1 (en) | 2006-10-05 |
| JP4729615B2 (en) | 2011-07-20 |
| JP2008534014A (en) | 2008-08-28 |
| IL186234A0 (en) | 2008-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113631708B (en) | Methods and compositions for editing RNA | |
| CN114736901B (en) | Oligonucleotides for reducing PD-L1 expression | |
| JP7573520B2 (en) | Plasmids containing sequences encoding mRNAs with segmented poly(A) tails | |
| ES2732774T3 (en) | UTRs that increase the efficiency of translation of RNA molecules | |
| US20250295755A1 (en) | Mrna vaccine composition | |
| US20240200042A1 (en) | Limited self-replicating mrna molecular system, producing method and use | |
| CN116917470A (en) | PAN-RAS mRNA cancer vaccine | |
| CA2602730A1 (en) | Defective sindbis viral vectors | |
| EP4267593A2 (en) | Self-amplifying messenger rna | |
| JP5639736B2 (en) | Vector for integration of heterologous genes into the poxvirus genome | |
| WO2023178294A9 (en) | Compositions and methods for improved protein translation from recombinant circular rnas | |
| WO2018168586A1 (en) | Borna viral vector and utilization thereof | |
| US12186388B2 (en) | Interferon-producing universal sarbecovirus vaccines, and uses thereof | |
| AU736586B2 (en) | An infectious clone for human parainfluenza virus type 3 | |
| CN117004579A (en) | Recombinant oncolytic vaccinia virus and its applications | |
| CN115960900A (en) | CRISPR-dCas9-based gene-targeted demethylation method and its application | |
| CN116286911A (en) | A spliceable system for regulating viral replication in response to anoxic environment and its use | |
| CA3208244A1 (en) | Fully synthetic, long-chain nucleic acid for vaccine production to protect against coronaviruses | |
| WO2025011529A2 (en) | Circular rna vaccines for seasonal flu and methods of uses | |
| CN101948516B (en) | Establishment and application of vaccinia virus vector-based reverse genetics system | |
| US20250161433A1 (en) | Interferon-producing universal sarbecovirus vaccines, and uses thereof | |
| US20250188127A1 (en) | Biologically produced nucleic acid for vaccine production | |
| JP3638019B2 (en) | Recombinant Sendai virus | |
| CN103316337B (en) | Construction of vaccinia virus vector gene modification system, and application of recombinant coronavirus | |
| CN118175992A (en) | mRNA vaccine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20220301 |
|
| MKLA | Lapsed |
Effective date: 20200831 |